Cebaracetam
Discontinued experimental nootropic from the racetam family; its effect is unclear and there is little human data.
Pharmacology
Contents
DETAILED OVERVIEW
What is Cebaracetam?
Cebaracetam is an experimental compound from the racetam family, developed by Novartis (formerly Ciba-Geigy) for cognitive disorders, meaning a decline in thinking and memory. Development reached the second stage of clinical trials and was stopped in 1995. The compound was never marketed and was never approved for any medical use.
Its mechanism was never clearly established: early research pointed to effects on signaling between nerve cells (the acetylcholine and glutamate systems) and to protection against damage from lack of oxygen, but all of this was weak. There is practically no human data; the published material is limited to a single laboratory method paper (a urine test). Its safety in humans has never been established, so it should be avoided in pregnancy and breastfeeding, and any self-experimentation is strongly contraindicated. It does not replace evidence-based treatment. The purity and identity of material sold as a research chemical are a separate, unknown risk.
Mechanism
Undefined (weak cholinergic / glutamatergic)
Half-life
N/A (not characterized)
Onset
N/A (no validated protocol)
Status
Discontinued phase II (Novartis, 1995); unapproved
Because cebaracetam never reached the market and remained an obscure discontinued research compound, there is essentially no reliable body of user experience to report. It occasionally appears in racetam catalogues and enthusiast lists as a curiosity, but credible first-hand accounts are absent, and any circulating claims should be treated with skepticism. This entry exists as a reference and historical data point rather than a usage guide.
⚠ Not clinical evidence – based on user accounts.
Receptor profile
- Cholinergic transmissionWeak
- Glutamatergic (AMPA / NMDA) signalingWeak
- Neuronal resilience under ischemiaWeak
Safety
Side effects, stop signs, contraindications
Side effects · 4
- The human safety profile was never established; no long-term human safety data exist
- Because development was halted at phase II, no adverse-effect frequency data were ever published
- As with other racetams, cholinergic-type effects (such as headache) are plausible but unverified for this compound
- The purity and identity of any grey-market or research-chemical material is a separate, uncharacterized risk
Contraindications · 4
- Not for human consumption: an unapproved investigational compound with no established safety
- Pregnancy and breastfeeding: no data whatsoever, must be avoided
- Any self-experimentation is strongly discouraged given the absence of dosing, safety and interaction data
- Not a substitute for evidence-based cognitive treatments; consult a physician for genuine cognitive concerns
Related Nootropics
Same therapeutic category
Studies
Related research and clinical findings
FAQ
FAQ
Cebaracetam is an obscure, experimental compound from the racetam family, developed by Novartis for cognitive disorders, but development was discontinued at phase II clinical trials. It was studied preclinically (in animals) for memory and learning problems and for possible neuroprotection under low-oxygen stress, but none of this was ever confirmed in humans. In practice it is mostly a historical curiosity within the racetam family, not an established or well-documented substance.
Telegram
Have a question about Cebaracetam?
Reach out to us on Telegram for a personalized stack. We'll be happy to help.
Personalized consultation
Want a detailed conversation tailored to your data?
Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.
Fill out the form~5–7 min · prep questionnaire · confidential · GDPR-compliant
Structure & chemistry
The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.